Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.

Michels MAHM, van de Kar NCAJ, van den Bos RM, van der Velden TJAM, van Kraaij SAW, Sarlea SA, Gracchi V, Oosterveld MJS, Volokhina EB, van den Heuvel LPWJ.

Front Immunol. 2019 Jun 17;10:1350. doi: 10.3389/fimmu.2019.01350. eCollection 2019.

2.

Placental passage of eculizumab and complement blockade in a newborn.

Duineveld C, Wijnsma KL, Volokhina EB, van den Heuvel LPB, van de Kar NCAJ, Wetzels JFM.

Kidney Int. 2019 Apr;95(4):996. doi: 10.1016/j.kint.2019.01.012. No abstract available.

PMID:
30904074
3.

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab.

Wijnsma KL, Ter Heine R, Moes DJAR, Langemeijer S, Schols SEM, Volokhina EB, van den Heuvel LP, Wetzels JFM, van de Kar NCAJ, Brüggemann RJ.

Clin Pharmacokinet. 2019 Jul;58(7):859-874. doi: 10.1007/s40262-019-00742-8. Review.

4.

Correction to: Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.

Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ.

Pediatr Nephrol. 2019 Apr;34(4):741-742. doi: 10.1007/s00467-018-4186-x.

5.

Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.

Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ.

Pediatr Nephrol. 2019 Nov;34(11):2261-2277. doi: 10.1007/s00467-018-4091-3. Epub 2018 Nov 6. Review. Erratum in: Pediatr Nephrol. 2019 Jan 15;:.

6.

Validity of the Patient Experiences and Satisfaction with Medications (PESaM) Questionnaire.

Kimman ML, Wijsenbeek MS, van Kuijk SMJ, Wijnsma KL, van de Kar NCAJ, Storm M, van Jaarsveld X, Dirksen CD; PESaM Collaborating Group.

Patient. 2019 Feb;12(1):149-162. doi: 10.1007/s40271-018-0340-6.

7.

Glyco-iELISA: a highly sensitive and unambiguous serological method to diagnose STEC-HUS caused by serotype O157.

Wijnsma KL, Veissi ST, van Bommel SAM, Heuver R, Volokhina EB, Comerci DJ, Ugalde JE, van de Kar NCAJ, van den Heuvel LPWJ.

Pediatr Nephrol. 2019 Apr;34(4):631-639. doi: 10.1007/s00467-018-4118-9. Epub 2018 Oct 26.

8.

Benefit of Eculizumab Compared to Standard of Care Still Unproven in C3 Glomerulopathy.

Duineveld C, van de Kar NCAJ, Wetzels JFM.

Am J Kidney Dis. 2018 Dec;72(6):906. doi: 10.1053/j.ajkd.2018.07.013. Epub 2018 Sep 17. No abstract available.

PMID:
30236630
9.

The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?

Michels MAHM, Volokhina EB, van de Kar NCAJ, van den Heuvel LPWJ.

Pediatr Nephrol. 2019 Aug;34(8):1349-1367. doi: 10.1007/s00467-018-4042-z. Epub 2018 Aug 23.

10.

Clinical and genetic analyses of a Dutch cohort of 40 patients with a nephronophthisis-related ciliopathy.

Stokman MF, van der Zwaag B, van de Kar NCAJ, van Haelst MM, van Eerde AM, van der Heijden JW, Kroes HY, Ippel E, Schulp AJA, van Gassen KL, van Rooij IALM, Giles RH, Beales PL, Roepman R, Arts HH, Bongers EMHF, Renkema KY, Knoers NVAM, van Reeuwijk J, Lilien MR.

Pediatr Nephrol. 2018 Oct;33(10):1701-1712. doi: 10.1007/s00467-018-3958-7. Epub 2018 Jul 5.

11.

Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.

Michels MAHM, van de Kar NCAJ, Okrój M, Blom AM, van Kraaij SAW, Volokhina EB, van den Heuvel LPWJ.

Front Immunol. 2018 Apr 4;9:612. doi: 10.3389/fimmu.2018.00612. eCollection 2018.

12.

The genetics of atypical hemolytic uremic syndrome.

Feitz WJC, van de Kar NCAJ, Orth-Höller D, van den Heuvel LPJW, Licht C.

Med Genet. 2018;30(4):400-409. doi: 10.1007/s11825-018-0216-0. Epub 2018 Dec 21. Review.

13.

Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome.

Wijnsma KL, Duineveld C, Volokhina EB, van den Heuvel LP, van de Kar NCAJ, Wetzels JFM.

Nephrol Dial Transplant. 2018 Apr 1;33(4):635-645. doi: 10.1093/ndt/gfx196.

PMID:
29106598
14.

REducing STEroids in Relapsing Nephrotic syndrome: the RESTERN study- protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study.

Schijvens AM, Dorresteijn EM, Roeleveld N, Ter Heine R, van Wijk JAE, Bouts AHM, Keijzer-Veen MG, van de Kar NCAJ, van den Heuvel LPWJ, Schreuder MF.

BMJ Open. 2017 Sep 27;7(9):e018148. doi: 10.1136/bmjopen-2017-018148.

15.

Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.

Duineveld C, Verhave JC, Berger SP, van de Kar NCAJ, Wetzels JFM.

Am J Kidney Dis. 2017 Dec;70(6):770-777. doi: 10.1053/j.ajkd.2017.06.024. Epub 2017 Aug 16.

PMID:
28821363
16.

Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire).

Kimman ML, Rotteveel AH, Wijsenbeek M, Mostard R, Tak NC, van Jaarsveld X, Storm M, Wijnsma KL, Gelens M, van de Kar NCAJ, Wetzels J, Dirksen CD.

Patient. 2017 Oct;10(5):629-642. doi: 10.1007/s40271-017-0234-z.

17.

Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2.

Wijnsma KL, Schijvens AM, Rossen JWA, Kooistra-Smid AMDM, Schreuder MF, van de Kar NCAJ.

Pediatr Nephrol. 2017 Jul;32(7):1263-1268. doi: 10.1007/s00467-017-3642-3. Epub 2017 Mar 25.

18.

Re: Bevill et al.: The Modern Metabolic Stone Evaluation in Children (Urology 2017;101:15-20).

Schreuder MF, van de Kar NC.

Urology. 2017 Apr;102:267-268. doi: 10.1016/j.urology.2016.12.054. Epub 2017 Jan 6. No abstract available.

PMID:
28069331
19.

Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome.

Westra D, Volokhina EB, van der Molen RG, van der Velden TJ, Jeronimus-Klaasen A, Goertz J, Gracchi V, Dorresteijn EM, Bouts AH, Keijzer-Veen MG, van Wijk JA, Bakker JA, Roos A, van den Heuvel LP, van de Kar NC.

Pediatr Nephrol. 2017 Feb;32(2):297-309. doi: 10.1007/s00467-016-3496-0. Epub 2016 Oct 7.

20.

Drug-Drug Interactions in Treatment Using Azole Antifungal Agents.

Schreuder MF, van de Kar NC, Brüggemann RJ.

JAMA. 2016 Jun 21;315(23):2622. doi: 10.1001/jama.2016.3820. No abstract available.

PMID:
27327812
21.

Fecal diagnostics in combination with serology: best test to establish STEC-HUS.

Wijnsma KL, van Bommel SA, van der Velden T, Volokhina E, Schreuder MF, van den Heuvel LP, van de Kar NC.

Pediatr Nephrol. 2016 Nov;31(11):2163-70. doi: 10.1007/s00467-016-3420-7. Epub 2016 May 30.

22.

Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.

Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C.

Kidney Int. 2016 Mar;89(3):701-11. doi: 10.1016/j.kint.2015.11.026. Epub 2016 Jan 28.

23.

Complement Factor H Serum Levels Determine Resistance to Pneumococcal Invasive Disease.

van der Maten E, Westra D, van Selm S, Langereis JD, Bootsma HJ, van Opzeeland FJ, de Groot R, Ruseva MM, Pickering MC, van den Heuvel LP, van de Kar NC, de Jonge MI, van der Flier M.

J Infect Dis. 2016 Jun 1;213(11):1820-7. doi: 10.1093/infdis/jiw029. Epub 2016 Jan 21.

24.

A young girl with an unusual cause of acute kidney injury: Answers.

Binkhorst M, Wijnsma KL, Steenbergen EJ, van de Kar NC, Schreuder MF.

Pediatr Nephrol. 2016 Nov;31(11):2075-8. doi: 10.1007/s00467-015-3171-x. Epub 2015 Aug 20. No abstract available.

25.

A young girl with an unusual cause of acute kidney injury: Questions.

Binkhorst M, Wijnsma KL, Steenbergen EJ, van de Kar NC, Schreuder MF.

Pediatr Nephrol. 2016 Nov;31(11):2071-3. doi: 10.1007/s00467-015-3170-y. Epub 2015 Aug 20. No abstract available.

26.

Advances and challenges in the management of complement-mediated thrombotic microangiopathies.

Davin JC, van de Kar NC.

Ther Adv Hematol. 2015 Aug;6(4):171-85. doi: 10.1177/2040620715577613. Review.

27.

Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo.

Volokhina EB, Bergseth G, van de Kar NC, van den Heuvel LP, Mollnes TE.

Blood. 2015 Jul 9;126(2):278-9. doi: 10.1182/blood-2015-03-637645. No abstract available.

28.

Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome.

Volokhina EB, van de Kar NC, Bergseth G, van der Velden TJ, Westra D, Wetzels JF, van den Heuvel LP, Mollnes TE.

Clin Immunol. 2015 Oct;160(2):237-43. doi: 10.1016/j.clim.2015.05.018. Epub 2015 Jun 23.

29.

Shiga Toxin/Verocytotoxin-Producing Escherichia coli Infections: Practical Clinical Perspectives.

Davis TK, Van De Kar NC, Tarr PI.

Microbiol Spectr. 2014 Aug;2(4):EHEC-0025-2014. doi: 10.1128/microbiolspec.EHEC-0025-2014. Review.

PMID:
26104210
30.

An international consensus approach to the management of atypical hemolytic uremic syndrome in children.

Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Frémeaux-Bacchi V; HUS International.

Pediatr Nephrol. 2016 Jan;31(1):15-39. doi: 10.1007/s00467-015-3076-8. Epub 2015 Apr 11. Review.

PMID:
25859752
31.

Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome.

Wetzels JF, van de Kar NC.

Am J Kidney Dis. 2015 Feb;65(2):342. doi: 10.1053/j.ajkd.2014.04.039. No abstract available.

PMID:
25616634
32.

Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.

Verhave JC, Wetzels JF, van de Kar NC.

Nephrol Dial Transplant. 2014 Sep;29 Suppl 4:iv131-41. doi: 10.1093/ndt/gfu235. Review.

PMID:
25165180
33.

Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission.

Volokhina EB, Westra D, van der Velden TJ, van de Kar NC, Mollnes TE, van den Heuvel LP.

Clin Exp Immunol. 2015 Aug;181(2):306-13. doi: 10.1111/cei.12426.

34.

Compound heterozygous mutations in the C6 gene of a child with recurrent infections.

Westra D, Kurvers RA, van den Heuvel LP, Würzner R, Hoppenreijs EP, van der Flier M, van de Kar NC, Warris A.

Mol Immunol. 2014 Apr;58(2):201-5. doi: 10.1016/j.molimm.2013.11.023. Epub 2013 Dec 30.

PMID:
24378253
35.

Adult renal size is not a suitable marker for nephron numbers: an individual patient data meta-analysis.

Bueters RR, van de Kar NC, Schreuder MF.

Kidney Blood Press Res. 2013;37(6):540-6. doi: 10.1159/000355734. Epub 2013 Nov 18.

36.

Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib.

van Balen T, Schreuder MF, de Jong H, van de Kar NC.

Eur J Haematol. 2014 Jan;92(1):80-2. doi: 10.1111/ejh.12206. Epub 2013 Oct 24.

PMID:
24118335
37.

Living kidney transplantation in adult patients with atypical haemolytic uraemic syndrome.

Verhave JC, Westra D, van Hamersvelt HW, van Helden M, van de Kar NC, Wetzels JF.

Neth J Med. 2013 Sep;71(7):342-7.

38.

Severe infantile Bordetella pertussis pneumonia in monozygotic twins with a congenital C3 deficiency.

Kurvers RA, Westra D, van Heijst AF, Walk TL, Warris A, van de Kar NC.

Eur J Pediatr. 2014 Dec;173(12):1591-4. doi: 10.1007/s00431-013-2107-3. Epub 2013 Aug 21.

PMID:
23963626
39.

Combined pulmonary hypertension and renal thrombotic microangiopathy in cobalamin C deficiency.

Kömhoff M, Roofthooft MT, Westra D, Teertstra TK, Losito A, van de Kar NC, Berger RM.

Pediatrics. 2013 Aug;132(2):e540-4. doi: 10.1542/peds.2012-2581. Epub 2013 Jul 8.

PMID:
23837176
40.

The challenge of managing hemophilia A and STEC-induced hemolytic uremic syndrome.

Westra D, Dorresteijn EM, Beishuizen A, van den Heuvel LP, Brons PP, van de Kar NC.

Pediatr Nephrol. 2013 Feb;28(2):349-52. doi: 10.1007/s00467-012-2312-8. Epub 2012 Sep 23.

PMID:
23001024
41.

Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H-related 5 gene.

Westra D, Vernon KA, Volokhina EB, Pickering MC, van de Kar NC, van den Heuvel LP.

J Hum Genet. 2012 Jul;57(7):459-64. doi: 10.1038/jhg.2012.57. Epub 2012 May 24.

42.

Cat induced Pasteurella multocida peritonitis in peritoneal dialysis: a case report and review of the literature.

Sol PM, van de Kar NC, Schreuder MF.

Int J Hyg Environ Health. 2013 Mar;216(2):211-3. doi: 10.1016/j.ijheh.2012.04.003. Epub 2012 May 7. Review.

PMID:
22572039
43.

A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome.

Westra D, Wetzels JF, Volokhina EB, van den Heuvel LP, van de Kar NC.

Neth J Med. 2012 Apr;70(3):121-9. Review.

44.

Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics.

Geerdink LM, Westra D, van Wijk JA, Dorresteijn EM, Lilien MR, Davin JC, Kömhoff M, Van Hoeck K, van der Vlugt A, van den Heuvel LP, van de Kar NC.

Pediatr Nephrol. 2012 Aug;27(8):1283-91. doi: 10.1007/s00467-012-2131-y. Epub 2012 Mar 13.

45.

Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count.

Dorresteijn EM, van de Kar NC, Cransberg K.

Pediatr Nephrol. 2012 Jul;27(7):1193-5. doi: 10.1007/s00467-012-2130-z. Epub 2012 Mar 8.

46.

Renal transplantation in patients with atypical haemolytic uraemic syndrome: a tailor made approach is necessary.

van der Wijk J, Smid WM, Seelen MA, van de Kar NC, Offerman JJ, van Son WJ.

Neth J Med. 2011 Jun;69(6):279-80.

47.

Unexplained hypothermia and bradycardia in two pediatric patients with Wegener's granulomatosis.

Geerdink LM, Koster-Kamphuis L, Cornelissen EA, Willemsen MA, van de Kar NC.

Pediatr Nephrol. 2011 Feb;26(2):325-6. doi: 10.1007/s00467-010-1635-6. Epub 2010 Aug 22. No abstract available.

48.

The spectrum of phenotypes caused by variants in the CFH gene.

Boon CJ, van de Kar NC, Klevering BJ, Keunen JE, Cremers FP, Klaver CC, Hoyng CB, Daha MR, den Hollander AI.

Mol Immunol. 2009 May;46(8-9):1573-94. doi: 10.1016/j.molimm.2009.02.013. Epub 2009 Mar 17. Review.

PMID:
19297022
49.
50.

Metastatic rhabdomyosarcoma cured after chemotherapy and allogeneic SCT.

Donker AE, Hoogerbrugge PM, Mavinkurve-Groothuis AM, van de Kar NC, Boetes C, Hulsbergen-van de Kaa CA, Groot-Loonen JJ.

Bone Marrow Transplant. 2009 Jan;43(2):179-80. doi: 10.1038/bmt.2008.301. Epub 2008 Sep 1. No abstract available.

PMID:
18762761

Supplemental Content

Loading ...
Support Center